UCB net profit was EUR103m for the full-year of 2010, compared to EUR513m for the same period in 2009.
Net sales for the full-year of 2010 were EUR2.78bn, compared to EUR2.68bn.
The company has earned gross profit of EUR2.16bn, compared to EUR2.09bn for the same period last year.
Total revenue is expected between EUR3bn and EUR3.1bn in 2011 due to generic competition to Keppra in the EU and the full annualized generic competition to US products as well as further erosion of mature products, partially offset by the performance of newly launched products.
UCB CEO Roch Doliveux said following the strong delivery in 2010, UCB has now entered the last part of its transformation into a patient-centric global biopharmaceutical with intense growth of our new products and a promising pipeline.
"The intense growth of Cimzia, Vimpat and Neupro is expected to compensate to a large extent – but not entirely – the effects of the last wave of major patent expiries expected in 2011," Doliveux said.